SeaSpine to Participate in the Canaccord Genuity Virtual Musculoskeletal Conference
SeaSpine Holdings Corporation (NASDAQ: SPNE) will present at the Canaccord Genuity Virtual Musculoskeletal Conference on May 20, 2021, at 1:00 PM ET. The presentation will focus on their innovative surgical solutions for spinal disorders. A live and archived webcast will be accessible on the Investor Relations page of their website. SeaSpine specializes in orthobiologics and spinal implants, aiming to enhance bone fusion rates for various orthopedic surgeries. Their products are marketed in the U.S. and around 30 countries through exclusive distribution partners.
- None.
- None.
CARLSBAD, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the Company will present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021, beginning at 1:00 PM ET.
A live and archived webcast of the event will be available from the Investor Relations page of the Company's website at investor.seaspine.com.
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.
Investor Relations Contact
Leigh Salvo
(415) 937-5402
ir@seaspine.com
FAQ
When is SeaSpine's presentation at the Canaccord Genuity Virtual Musculoskeletal Conference?
How can I watch SeaSpine's presentation live?
What is SeaSpine's focus in the medical technology sector?
In how many countries does SeaSpine market its products?